Refractory Disease in ATTR-CM: Tafamidis and Treatment Decisions

Clinical Summary

In ATTR-CM, “refractory” disease is often better understood as persistent progression, congestion, or functional decline despite transthyretin-directed therapy rather than clear-cut failure of a single agent. Tafamidis remains central because it stabilizes transthyretin and can slow further amyloid-related injury, but it does not reverse established myocardial infiltration ¹. When symptoms, biomarker activity, or recurrent decompensation continue on tafamidis, the more useful question is often whether the patient has advanced substrate, delayed treatment initiation, or imperfect persistence rather than simple binary nonresponse ^1,3.

That makes refractory ATTR-CM a longitudinal management problem. Clinical trajectory depends not only on whether disease-modifying therapy was started early enough, but also on whether it can be continued consistently and paired with heart-failure care that addresses congestion, rhythm issues, blood pressure reserve, and frailty ². Real-world persistence matters here: interrupted access, tolerability problems, or imperfect adherence can make ATTR-CM appear more treatment-resistant than it is biologically ³.

Acoramidis fits into the same treatment logic. It is an oral transthyretin stabilizer intended to reduce recurrent and cumulative cardiovascular outcomes, not to reverse fixed cardiac damage, so its role in refractory ATTR-CM still depends on persistence, tolerability, and how much disease remains modifiable ^1,4. In patients with ongoing decompensation despite a stabilizer-based regimen, it is better viewed as continued disease suppression than as rescue therapy for advanced structural disease.

When the course looks unexpectedly refractory, diagnostic reassessment remains important. Serum and urine immunofixation with serum free light chain testing are still needed to exclude AL amyloidosis or mixed disease, while TTR genetic testing clarifies hereditary versus nonhereditary ATTR-CM without by itself explaining refractoriness ³. Imaging has a similar role: 99mTc-PYP scintigraphy anchors the ATTR diagnosis, and echocardiography or cardiac MRI can help revisit whether persistent symptoms reflect amyloid burden, hemodynamic stress, or another confounder, although neither modality alone defines treatment failure ². NT-proBNP and troponin can add practical signal when symptoms and imaging do not align, but they remain context-dependent rather than definitive response measures ⁴.

As disease advances, management tends to hinge on feasibility and sequencing rather than a single rescue maneuver. For some patients, that means continuing tafamidis or another transthyretin stabilizer if it is tolerated and still plausibly modifying disease; for others, supportive care carries most of the clinical burden and needs to be optimized accordingly ^1-2. The central clinical tension is whether the current picture reflects persistent amyloid activity that can still be influenced, advanced myocardial damage that is only partly reversible, or a mixture of both.